2022
The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy.
Micevic G, Bosenberg M, Yan Q. The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy. Clinical Cancer Research 2022, 29: 1173-1182. PMID: 36449280, PMCID: PMC10073242, DOI: 10.1158/1078-0432.ccr-22-0784.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune checkpoint inhibitorsImmune checkpoint therapyT cell exhaustionCheckpoint therapyAntitumor immune responseT cell populationsCell-intrinsic immunityTypes of cancerViral mimicry responseLow response rateCheckpoint inhibitorsCurrent immunotherapiesPancreatic cancerSustained responsePreclinical modelsTreatment outcomesImmune responseEndogenous antigensResponse rateTumor typesMultiple epigenetic regulatorsCritical mediatorLow immunogenicityTherapyCancer
2016
Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors
Brooks ED, Schoenhals JE, Tang C, Micevic G, Gomez DR, Chang JY, Welsh JW. Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. The Cancer Journal 2016, 22: 257-266. PMID: 27441745, PMCID: PMC5812885, DOI: 10.1097/ppo.0000000000000210.Peer-Reviewed Original ResearchConceptsStereotactic ablative radiation therapyImmune checkpoint therapyAblative radiation therapyRadiation therapyNovel therapeuticsImmune checkpoint inhibitionImmune checkpoint inhibitorsLocal treatment optionsEncouraging clinical responsesClinical responseExperience relapseSystemic therapyTreatment optionsClinical studiesLocal irradiationSystemic effectsImmunogenic effectsImmunotherapySolid tumorsTherapyNumerous cancersTumorsTherapeuticsRelapsePatients